Thus, the diminished activated TNFRSF4+ Tregs in tumor lesions are associated with the positive clinical outcome and could be used as potential predictors and therapeutic targets for neoadjuvant chemoimmunotherapy. This evidence concerns the gene TNFRSF4 and neoplasm.